EGFR and lung cancer: In 2021, Jiang group developed two highly selective and functional EGFR-targeting PROTAC 30 (SIAIS125, Fig. 7) and 31 (SIAIS126, Fig. 7) based on Canertinib and CRBN ligand.57 Interestingly, they induced sustaining and selective degradation of EGFRL858R/T790M in H1975 cells and EGFRe19d in PC9 cells rather than EGFREe19d/T790M in PC9Brca1 cells and EGFRWT in A549 cells, which led to the selective growth inhibition of EGFR mutant lung cancer cells instead of normal cells or A549 cells.